Loading...
XAMS
VVY
Market cap37mUSD
Jun 19, Last price  
1.10EUR
1D
0.92%
1Q
-14.73%
Jan 2017
-93.78%
IPO
-95.27%
Name

Vivoryon Therapeutics NV

Chart & Performance

D1W1MN
XAMS:VVY chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.20%
Rev. gr., 5y
%
Revenues
0k
21,0006,0000000000010,764,0000-3,620,00000
Net income
-9m
L-56.96%
-16,307,000-18,720,000-9,929,000-11,437,000-13,505,000-13,891,000-8,009,000-7,737,000-7,823,000-16,510,000-12,655,000-28,156,000-28,342,000-20,568,000-8,853,000
CFO
-8m
L-55.90%
-14,321,000-12,040,000-8,526,000-10,589-12,147-13,255-12,117-6,994-11,608,000-14,012,000-11,257,000-21,794,000-21,541,000-19,174,000-8,455,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for Alzheimer's disease. Their primary strategy involves targeting and inhibiting the production of toxic pyroglutamate-Abeta (pGlu-Abeta). The company's lead investigational compound, PQ912, is a small molecule QC inhibitor. This candidate has successfully completed Phase IIb clinical trials for both Alzheimer's disease and cancer. In its preclinical pipeline, Vivoryon is advancing PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor, specifically for cancer treatment. Additionally, the firm is developing a monoclonal antibody designed to enhance the clearance of pGlu-Abeta. Vivoryon Therapeutics maintains a robust network of collaborations, including a research agreement with University Medical Center Schleswig-Holstein focused on cancer immunotherapy, and a partnership with Nordic Bioscience for the clinical advancement of PQ912 in Alzheimer's disease. Further alliances include a research collaboration with the Fraunhofer Institute for cell therapy and immunology, and a strategic regional licensing agreement with Simcere Pharmaceutical Group Ltd. This latter partnership aims to develop and commercialize medicines specifically targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to address Alzheimer's disease. Established in 1997, Vivoryon Therapeutics N.V. is headquartered in Halle, Germany.
URL
https://www.vivoryon.com/
IPO date
Oct 27, 2014
Employees
15
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT